John Maraganore, PhD

John was born in Chicago, Illinois, U.S. in 1962 to Greek immigrant parents. He has a B.A. (1984), M.S. (1985), and Ph.D. (1986) from the University of Chicago in the Division of Biological Sciences. Maraganore started his career as a post-doctoral research scientist at Upjohn from 1985-86. From 1986-87, he was a senior scientist at Zymogenetics. From 1987-1997, he was at Biogen in Cambridge, Massachusetts. At Biogen, he invented bivalirudin, a direct-acting thrombin inhibitor, later commercialized in the U.S. as ANGIOMAXTM. In 1997, Maraganore joined Millennium Pharmaceuticals in a number of senior leadership roles. From 2002-2021, John served as the founding CEO and a Director at Alnylam Pharmaceuticals. At Alnylam, he led the company’s pioneering efforts to advance RNA interference therapeutics, bringing 6 approved products to market and building $25 billion in market capitalization. On 12/31/21, John transitioned CEO leadership of Alnylam to Yvonne Greenstreet. Maraganore was Chair